Stocks
Artelo Biosciences, Inc.ARTL
NASDAQHealthcareBiotechnology$2.66
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing cannabinoid-based therapies for conditions including anorexia, pain, and inflammation. Its lead candidate, ART27.13, targets chemotherapy-induced anorexia and is in Phase 1/2 trials. Investors track the stock for its exposure to the emerging cannabinoid drug development space and its pipeline progress.
52W Range: $2.66-$179.19
Congressional Interest in Artelo Biosciences, Inc. (ARTL)
No congressional trades have been disclosed for Artelo Biosciences, Inc. (ARTL) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading ARTL?
No congressional trades found for this stock.